Class Action

Combivent Respimat Asthma Inhalers

Class Action

Combivent Respimat Asthma Inhalers

In May 2019, a class-action lawsuit was filed against Boehringer Ingelheim Pharmaceuticals for allegedly deceptively marketing that the Combivent Respimat asthma inhaler will provide 120 doses when, according to plaintiffs, the inhaler contains far fewer dosages, sometimes less than half the advertised amount. (Ignacuinos et al v. Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-672, D. Conn.)


The Latest

Filters

TINA.org Files FTC Complaint against Homeaglow

Press Release

TINA.org Files FTC Complaint against Homeaglow

MADISON, CONN. Sept. 9, 2025 – An investigation by consumer advocacy organization truthinadvertising.org (TINA.org) has found that Homeaglow is deceptively advertising $19 home cleanings in order to lure consumers into…


Show More